STOCK TITAN

Atricure Stock Price, News & Analysis

ATRC NASDAQ

Company Description

Overview of AtriCure

AtriCure (ATRC) is a renowned medical device company committed to transforming the landscape of cardiac care through its innovative surgical solutions. With expertise in the treatment of atrial fibrillation and effective management of the left atrial appendage, the company develops advanced, minimally invasive technologies designed for both electrophysiologists and cardiothoracic surgeons. The product portfolio is built on clinically validated approaches and engineered precision, ensuring that patients receive safe and effective surgical interventions in the field of cardiac care.

Core Technologies and Solutions

AtriCure’s offerings include a comprehensive range of products that address critical aspects of atrial fibrillation treatment and cardiac surgical procedures. These solutions include:

  • Ablation Systems: Designed to create precise lesions for disrupting abnormal electrical signals, these systems are integral in treating persistent atrial fibrillation.
  • Cryotherapy Devices: Employed in freezing techniques that minimize damage to surrounding tissues, enhancing the safety and efficacy of the procedure.
  • Soft Tissue Dissection Tools: Engineered to facilitate minimally invasive surgery, these tools aid in reducing patient recovery time and surgical complications.
  • Left Atrial Appendage Management Solutions: Recognized for their widespread adoption, these devices are crucial in reducing stroke risk associated with atrial fibrillation by managing the left atrial appendage efficiently.

Business Model and Market Position

AtriCure operates through a robust business model that leverages both direct sales forces and distributor networks to connect with medical centers, primarily in the United States. The company emphasizes technology innovation and product reliability to position itself as a key player within the specialized segment of cardiac surgical devices. Its strategic focus has led to the development of systems that not only address the immediate surgical needs but also integrate into the broader framework of cardiac care protocols.

Innovative Approach to Cardiac Care

At the core of AtriCure’s success is its commitment to continuous innovation in surgical treatment. The company’s products are designed to facilitate minimally invasive procedures, ensuring that surgical teams can operate more efficiently while also enhancing patient outcomes. This approach represents a significant advancement in cardiac care, as it reduces procedural risks and supports the growing trend toward less invasive, more patient-friendly surgery options.

Competitive Landscape and Differentiation

Within the highly competitive medical device sector, AtriCure distinguishes itself through its relentless focus on clinical efficacy and precision engineering. Unlike generalized medical device companies, AtriCure targets niche clinical applications that require specialized expertise and technological sophistication. By securing critical regulatory approvals and embedding clinical insights into its product design, the company reflects a blend of deep industry knowledge and operational excellence.

Expertise and Industry Impact

The company demonstrates its expertise by continuously refining its technologies based on real-world clinical feedback and advancements in medical science. Healthcare professionals rely on AtriCure’s systems not only for their proven clinical benefits but also for the trust and reliability associated with their long-standing track record. This commitment to innovation and quality makes the company a respected contributor to the evolving landscape of cardiac surgery.

Operational Excellence and Sales Strategy

AtriCure’s operational model incorporates both a direct sales team and a network of distributors, ensuring extensive market reach and personalized customer engagement. This strategy allows the company to maintain strong relationships with leading medical institutions and adapt rapidly to the nuanced needs of healthcare providers, thus reinforcing its position as a trusted partner in advanced cardiac care.

Overall, AtriCure’s diverse product range, strategic market focus, and commitment to innovation underpin its significant role in modern cardiac care. Through its advanced surgical solutions, the company continues to contribute to improved patient outcomes and enhanced operational efficiency in the realm of minimally invasive cardiac procedures.

Stock Performance

$—
0.00%
0.00
Last updated:
46.42 %
Performance 1 year
$1.6B
Market Cap
49.5M
Shares outstanding

SEC Filings

No SEC filings available for Atricure.

Financial Highlights

$115,910,000
Revenue (TTM)
-$7,853,000
Net Income (TTM)
-$0.17
Diluted EPS (TTM)
$20,004,000
Operating Cash Flow
-6.78%
Net Profit Margin
-6.39%
Oper. Profit Margin

Upcoming Events

April 29, 2025
Release Q1 2025 results
April 29, 2025
Q1 2025 earnings call

Frequently Asked Questions

What is the current stock price of Atricure (ATRC)?

The current stock price of Atricure (ATRC) is $33.75 as of April 24, 2025.

What is the market cap of Atricure (ATRC)?

The market cap of Atricure (ATRC) is approximately 1.6B.

What is the revenue (TTM) of Atricure (ATRC) stock?

The trailing twelve months (TTM) revenue of Atricure (ATRC) is $115,910,000.

What is the net income of Atricure (ATRC)?

The trailing twelve months (TTM) net income of Atricure (ATRC) is -$7,853,000.

What is the earnings per share (EPS) of Atricure (ATRC)?

The diluted earnings per share (EPS) of Atricure (ATRC) is -$0.17 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Atricure (ATRC)?

The operating cash flow of Atricure (ATRC) is $20,004,000.

What is the profit margin of Atricure (ATRC)?

The net profit margin of Atricure (ATRC) is -6.78%.

What is the operating margin of Atricure (ATRC)?

The operating profit margin of Atricure (ATRC) is -6.39%.

What is the gross margin of Atricure (ATRC)?

The gross profit margin of Atricure (ATRC) is 74.88%.

What is the current ratio of Atricure (ATRC)?

The current ratio of Atricure (ATRC) is 3.62, indicating the company's ability to pay short-term obligations.

What is the gross profit of Atricure (ATRC)?

The gross profit of Atricure (ATRC) is $86,793,000 on a trailing twelve months (TTM) basis.

What is the operating income of Atricure (ATRC)?

The operating income of Atricure (ATRC) is -$7,405,000.

What is AtriCure's core business?

AtriCure specializes in developing advanced surgical technologies for the treatment of atrial fibrillation and managing left atrial appendage issues. The company focuses on minimally invasive cardiac solutions that enhance patient outcomes.

What types of technologies does AtriCure offer?

AtriCure offers a diverse range of technologies including ablation systems, cryotherapy devices, and soft tissue dissection tools. These products are designed to enable precise, minimally invasive procedures in cardiac care.

How does AtriCure improve atrial fibrillation treatment?

Through its innovative ablation systems and associated technologies, AtriCure provides surgical solutions that disrupt abnormal electrical activity in the heart. This approach helps manage persistent atrial fibrillation effectively.

What is the significance of AtriCure's left atrial appendage management solutions?

The left atrial appendage management systems are designed to reduce stroke risk by effectively excluding the problematic area. These devices have been widely adopted due to their clinical efficacy and role in comprehensive cardiac care.

How does AtriCure support minimally invasive surgical procedures?

AtriCure develops specialized devices that streamline minimally invasive procedures, reducing recovery time and surgical complications. Their innovative tools facilitate efficient access and treatment during complex cardiac surgeries.

Through which channels does AtriCure distribute its products?

The company uses a hybrid sales approach, incorporating both a direct sales team and an extensive network of distributors. This model ensures a broad market reach and strong relationships with medical centers.

Who are the primary users of AtriCure's technologies?

Electrophysiologists, cardiothoracic surgeons, and other cardiac care professionals are the main users of AtriCure's innovative solutions. These devices are integral to the treatment of atrial fibrillation and related cardiac conditions.

What differentiates AtriCure from other companies in the medical device industry?

AtriCure differentiates itself through its focused approach to cardiac care, regulatory-approved technologies, and commitment to minimally invasive solutions. Its emphasis on clinical efficacy and innovation sets it apart in a competitive market.